Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma

Summary

This is an open label, non-randomized phase 2 study to assess overall response rate (ORR), clinical benefit rate (CBR), overall survival (OS) and progression free survival (PFS) in patients with high grade neuroendocrine tumors treated with pembrolizumab 200mg Q 3 Weeks.

Timeline

Start

2017-12-04

Primary completion

2018-12-13

Completion

2019-03-11

Outcome

Outcome not reported

Stopped: “Update on clinical development: after discussions with the drug manufacturer, the PI has decided to discontinue the trial.”

Drugs

Indications